Japanese BAY1000394 Monotherapy Phase I Study

Summary

This is an open-label, non-randomized, dose-escalating Phase I study to evaluate the safety, tolerability, pharmacokinetics of BAY1000394 given in a 3 days on / 4 days off schedule in Japanese subjects with advanced malignancies.

Timeline

Start

2014-05-19

Primary completion

2015-01-06

Completion

2018-07-19

Drugs

Indications